Skip to main content

Russia vs Other Regulators

Overview

Russia's regulatory framework shares structural similarities with the European system (four risk classes, risk-based classification, technical documentation requirements aligned with EU MDR Annex II) but has several unique features that require dedicated compliance planning.

Key comparison

FeatureRussia (RZN)EU (MDR)USA (FDA)Australia (TGA)
ClassesI, IIa, IIb, IIII, IIa, IIb, IIII, II, IIII, IIa, IIb, III
Registration databaseGRLSEUDAMEDFDA 510(k)/PMA databaseARTG
Local representative requiredYes — RUS REPYes — EUAP (for non-EU)Yes — US AgentYes — Australian Sponsor
Clinical testing in-countryOften requiredGenerally notNot requiredNot required
QMS inspectionMandatory IIa sterile, IIb, IIIVia Notified BodyVia FDA inspectionVia TGA/MDSAP
Multi-country routeEAEU (5 countries)CE mark (EU/EEA)No equivalentNo equivalent
LanguageRussian mandatoryLocal languageEnglishEnglish

Key differences for manufacturers familiar with EU MDR

  • Local clinical testing is a significant additional requirement in Russia, particularly for Class IIb and III devices with no Russian-registered equivalent.
  • Russian-language translation of all documentation is mandatory — there is no flexibility on this point.
  • Two-phase review process is different from the EU conformity assessment model — Russia uses a state expert review system rather than Notified Body certification.
  • EAEU transition means manufacturers must eventually migrate to EAEU rules regardless of existing national registrations.

IMDRF membership

Russia is a member of the International Medical Device Regulators Forum (IMDRF). Russia chaired IMDRF in 2019. IMDRF guidance documents (including GHTF studies) are considered in Russian regulatory development, though implementation is not automatic.

Official source

IMDRF: imdrf.org